Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial
ConclusionIn patients with HFrEF and diabetes, there was no signal of harm and a trend towards benefit when direct renin inhibition monotherapy was compared with an angiotensin‐converting enzyme inhibitor, whereas combined aliskiren and enalapril treatment led to more adverse events with no improvement in outcomes. Treatment effects did not differ in patients with diabetes compared with those without. Clinical Trial Registration URL:
http://www.clinicaltrials.gov. Unique identifier: NCT00853658.
Source: European Journal of Heart Failure - Category: Cardiology Authors: S øren L. Kristensen, Ulrik M. Mogensen, Georgia Tarnesby, Claudio R. Gimpelewicz, Mohammed A. Ali, Qing Shao, YannTong Chiang, Pardeep S. Jhund, William T. Abraham, Kenneth Dickstein, John J.V. McMurray, Lars Køber Tags: Research Article Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Diabetes | Enalapril | Endocrinology | Georgia Health | Heart | Heart Failure | Study | Tekturna